Royal Bank of Canada
THRX

Royal Bank of Canada’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Royal Bank of Canada’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,615
Closed -$22K – 7847
2023
Q4 		$22K Sell
5,615
-1,141
-17% -$3.48K ﹤0.01% 6282
2023
Q3 		$18K Buy
6,756
+4,644
+220% +$18.2K ﹤0.01% 6225
2023
Q2 		$20K Buy
2,112
+1,083
+105% +$10.7K ﹤0.01% 6229
2023
Q1 		$9K Sell
1,029
-1,888
-65% -$18.5K ﹤0.01% 6383
2022
Q4 		$14K Buy
2,917
+2,711
+1,316% +$15.9K ﹤0.01% 6437
2022
Q3 		$1K Buy
206
+110
+115% +$777 ﹤0.01% 7336
2022
Q2 		$1K Sell
96
-611
-86% -$5.05K ﹤0.01% 7262
2022
Q1 		$8K Sell
707
-1,575
-69% -$16.8K ﹤0.01% 7077
2021
Q4 		$29K Buy
+2,282
New +$34.5K ﹤0.01% 6638

Royal Bank of Canada's THRX Position: Q1 2024 in Review

Royal Bank of Canada sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 5,615 shares — an estimated $22K sold.

Royal Bank of Canada first reported a position in THRX in Q4 2021 and held it in 9 quarters. The position peaked at $29K in Q4 2021. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

  • Royal Bank of Canada reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 5,615 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $22K.
  • Royal Bank of Canada first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • Royal Bank of Canada's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $29K in Q4 2021.
  • 1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Royal Bank of Canada's 13F filing for Q1 2024, filed 15 May 2024.